Lancet study underscores importance of AMR-Global’s recently awarded GLORIA project

A recent systematic analysis of the global burden of bacterial antimicrobial resistance published in The Lancet last week shows that antimicrobial resistance (AMR) poses a major threat to human health around the world and with the largest burden in sub-Saharan Africa and south Asia. The study includes the most comprehensive estimates of AMR burden to date and claims that roughly 4.95 million deaths were associated with bacterial AMR in 2019, 1.27 million of which can be directly attributed to AMR.

The accompanying editorial in The Lancet asserts that AMR is a major cause of death globally, “with a burden likely to be higher than that of HIV or malaria,” but while there have been clear warning signs and consistent calls for action, the reaction has been intermittent and unequal. The authors call upon the Global Fund to revise its mission and embrace AMR as one of its core responsibilities.

AMR-Global aims to lift barriers to development, evaluation, and implementation of interventions to combat AMR, with emphasis on innovations that matter for people in low- and middle-income countries. In this vein, the Lancet study highlights AMR-Global’s mission and emphasizes not only the demand for increased funding for AMR research and data collection, but also the urgency of this need.

Most recently, AMR-Global has kicked off the GLORIA program. GLORIA, or “AMR-Global: Reducing inappropriate exposure to antibiotics” is a collaboration co-funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. The program currently has two lines of research focused on reducing inappropriate antibiotic usage in LMIC and the development of improved point-of-care tests to distinguish between bacterial and viral infections.

Improving the understanding of the impact of AMR should be a very high priority for global health policy makers. Whilst this is well understood by the partners of AMR-Global, a more comprehensive global strategy towards solving AMR is needed to achieve equitable health, which is one of the main objectives of the UN Sustainable Development Goals.


Read more about the recently awarded GLORIA program on the AMR-Global website here.

Previous
Previous

Partnership Meeting

Next
Next

AMR-Global partners awarded grant for antibiotic resistance research program